Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The company is seeking to convert the vaccine’s emergency use authorization received in 2022 into a full approval that would ...

"I think the odds for approval went up quite a bit," B Riley analyst Mayank Mamtani said in an interview, adding that Wednesday's request from the FDA gave investors clarity on the path to ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...